High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

New England Journal of Medicine

Volumn 348, Issue 19, 2003, Pages 1875-1883

  Child, J Anthony ^a,c   Morgan, Gareth J ^a   Davies, Faith E ^a   Owen, Roger G ^a   Bell, Susan E ^a   Hawkins, Kim ^a   Brown, Julia ^a   Drayson, Mark T ^b   Selby, Peter J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CARMUSTINE; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; STEM CELL MOBILIZATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CAUSE OF DEATH; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 0037739753     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa022340     Document Type: Article

References (29)

1. MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992;2:200-5.
2. Child JA. Evolving strategies for the treatment of myelomatosis. Br J Haematol 1994; 88:672-8.
3. Samson D, Gaminara E, Newland A, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989;2: 882-5.
4. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;2:822-4.
5. Selby PJ, McElwain TJ, Nandi AC, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987;66:55-62.
6. Gore ME, Selby PJ, Viner C, et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989;2:879-82.
7. Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759-63.
8. Morgan G, Selby P. Myeloma. In: Souhami R, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology. 2nd ed. Vol. 2. Oxford, England: Oxford University Press, 2001:2419-55.
9. Blade J, San Miguel JF, Fontanillas M, et al. Survival of multiple myeloma patients who are potential candidates for early highdose therapy intensification/autotransplantation and who are conventionally treated. J Clin Oncol 1996;7:2167-73.
10. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-93.
11. Lenhoff S, Hjorth M, Holmberg E, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000;95:7-11.
12. Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
13. Fermand J-P, Ravaud P, Katsahian S, et al. High dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): results of a randomized trial in 190 patients 55 to 65 years of age. Blood 1999;94:Suppl 1:396a. abstract.
14. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
15. Review manager (RevMan), version 4.1. Oxford, England: Cochrane Collaboration, 2000.
16. Simnett SJ, Stewart LA, Sweetenham J, Morgan G, Johnson PW. Autologous stem cell transplantation for malignancy: a systematic review of the literature. Clin Lab Haematol 2000;22:61-72.
17. Blade J, Sureda A, Ribera JM, et al. Highdose therapy autotransplantation/intensification vs continued conventional chemotherapy in multiple myeloma patients responding to initial treatment chemotherapy: results of a prospective randomized trial from the Spanish Cooperative Group PETHEMA. Blood 2001;98:815a. abstract.
18. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-6.
19. Singer CRJ, Cavenagh J, Mills M, et al. Preliminary report of a multicentre randomised study of high dose or intermediate dose melphalan after initial VAD/VAMP therapy of myeloma. In: Proceedings of the VIII International Myeloma Workshop, Banff, Alta., May 4-8, 2001:140. abstract.
20. Segeren CM, Sonneveld P, Van der Holt B, et al. Myeloablative treatment following intensified chemotherapy in untreated multiple myeloma: a prospective, randomized phase III study. Blood 2001;98:815a. abstract.
21. Fermand J-P, Marolleau J-P, Alberti C, et al. Single versus tandem high dose therapy (HDT) supported with autologous blood stem cell (ABSC) transplantation using unselected or CD34 enriched ABSC: preliminary results of a two by two designed randomized trial in 230 young patients with multiple myeloma (MM). Blood 2001;98:815a. abstract.
22. Attal M, Harousseau JL, Facon T. Single versus double transplant in myeloma: a randomised trial of the Intergroupe Français du Myélome. In: Proceedings of the VIII International Myeloma Workshop, Banff, Alta., May 4-8, 2001:28. abstract.
23. Cavo M, Tosi P, Zamagni E, et al. The Bologna 96 clinical trial of single vs double PBSCT transplantation for previously untreated MM: results of an interim analysis. In: Proceedings of the VIII International Myeloma Workshop, Banff, Alta., May 4-8, 2001:29. abstract.
24. Cuzick J, Cooper EH, MacLennan IC. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer 1985; 52:1-6.
25. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001;97:1566-71.
26. Tricot G, Spencer T, Sawyer J, et al. Predicting long-term (≥5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002;116:211-7.
27. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
28. Lahuerta JJ, Martinez-Lopez J, Sema JD, et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000;109:438-46.
29. Davies FE, Forsyth PD, Rawstron AC, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001;112:814-9.